Showing 2561-2570 of 3069 results for "".
- First Patient Dosed in TrialSpark's Phase 2 Trial of ASN008-201 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-trailsparks-phase-2-trial-of-asn008-201-in-ad/2461736/The first patient has been dosed in TrialSpark’s Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 tr
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Green Living Environments Don't Protect Kids from Eczemahttps://practicaldermatology.com/news/green-living-environments-dont-protect-kids-from-eczema/2461675/Greenness or the significant presence of living vegetation around the home in early childhood does not seem to protect children from atopic eczema, a new Finnish study shows. Instead, the proximity of coniferous, mixed forests and agricultural areas was associated with elevated risk of
- AbbVie Enters Doc Film Biz: Company Releases New Film on Life with Eczemahttps://practicaldermatology.com/news/abbvie-enters-doc-film-biz-company-releases-new-film-on-living-with-eczema/2461609/AbbVie is releasing a new documentary film, “Under My Skin: Untold Stories of Life with Eczema,” which debuted at South by Southwest 2023 in Austin, Texas. The film, directed by Redglass Pictures, features the physical and emotional stories of three ind
- Ribon Therapeutics: First Patient Dosed in Phase 1 Study with RBN-3143 of ADhttps://practicaldermatology.com/news/ribon-therapeutics-first-patient-dosed-in-phase-1-study-with-rbn-3143-of-ad/2461599/Ribon Therapeutics dosed the first patient with RBN-3143 in the open-label cohort of patients with moderate-to-severe atopic dermatitis. The study aims to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in
- Let There Be Light: Lumohs Founder Donates Scalpels to Floating Doctorshttps://practicaldermatology.com/news/let-there-be-light-lumohs-founder-donates-scalpels-to-floating-doctors/2461595/Floating Doctors will be using the Lumohs scalpel when treating underserved patients in areas without electricity or water. The Floating Doctors' volunteer medical teams deploy by boat, packhorse, or on foot to remote underserved areas. The Lumohs is a pate
- Baby Dove Launches #BabySkin Advice on TikTok with Top Dermatologists and Pediatricianshttps://practicaldermatology.com/news/baby-dove-launches-babyskin-advice-on-tiktok-with-top-dermatologists-and-pediatricians/2461582/Baby Dove is launching #BabySkin Advice,' on TikTok The series provides expert advice from dermatologists and pediatricians to help parents in search of trusted products to care for their newborns unique and delicate skin needs. The #BabySkin Advice series will run from&n
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T